1
ANALGESIC EFFECT OF LARIMSH™ IN SERIES OF ELEVEN CHRONIC ARTHRITIS PATIENTS M. de la R osa-Viejo, R . R odrí guez-Pé rez, H. Lemus-Balcazar, M. Garcí a-Montañ é z and M.D. Ramí rez-González Hospital of Mother Theresa of Calcuta- Mé xico, Fascimex S.A., National Autonomous University of Mexico, Depts. of P hysiology and P harmacology T he word –arthritis - literally means joint inflammation, but it is often us ed more broadly to indicate any of the more than 100 chronic diseases of joints, bones and muscle. Two of the most common and best known types of arthritis are Os teoathritis , a form of cartilage wais t in the joints , and R heumatoid Arthritis , an immune system disease, that causes pain and disability as the result of joint inflammation. (1) Arthritis affects two times more women than men, it is also the rea- s on of 39 million medical cons ults and more than one million hos pilalizations each year, the estimated cost of ar- thritis to the economy is more than 64 billion dollars. (2) T here is no cure for mos t of the differ- ent types of arthritis . It’s been told than many forms of arthritis res pons e to an wide range of conventional treat- ments , automeditation and alternative therapies, but nothing conclusive. (2) In the treatment of this diseases with different drugs like: NS AIDs (Non steroideal aintiinflammatory drugs), DMAR Ds (Disease-modifying antirheumatic drugs), S teroids, Inmunosuppresors, S alicylates and Analgesics, is found that in most of them there are contraindications and nocive effects, specially damage of the gastrointestinal system, basically gastritis and ulcers. (3) INTRODUCTION LAR IMS H™ (LR ) is a Mexican Hydrocarbon product obtained via catalytic dis- tillation from crude oil. It contains 345 different compounds, among others: Al- kanes (Pentadekanes, hepta and octadecanes), alkanes-Isoprenoids (pristane and phytane), cycloparafins (naphtenes: cyclopentane, cyclohecane, decalin), aromatics, nitrogen-oxygen-sulphur coumpounds. The main characteristics are: average molecular weight: 250, sulphur content: 1.5% max., carbon: 85%, hy- drogen: 13%, nitrogen: 0.03% and oxygen: 0.4%. T he hydrocarbon fraction is further- more formulated with several com- pounds that contains chemical ele- ments from the fourth and sixth groups of the P eriodic Table of the E lements, then applies a radiation process with UV. (4) S tudies for the lethal effect of LR and its effects on body weight, food and water intake following acute and chronic treatment when given in different doses (0.001 to 30 g/kg) and routes of administration (topic and oral) to C D-1 male mice with an average body of 44 g. Lethal dose in mice was 21 g/kg (C.L. 10.94 - 41.2) which indicate a wide mar- gin of safety for this product. No change in body weight occurred with daily treatment up to 73 days with LR treatment. A significant loss of body hair (over 90% of the total fur) was observed by day 45th. The alopecia was reversed within three weeks when LR treatment was discontinued. Food and water in- take were significantly increased with greater effect observed with topic LR ( + vs + , P<0.05). E stimates of lethal dose in rats and mice (18 and 20 g/kg, respectively) indicate a wide margin of safety for this product. (Patent registration number of LAR IMS H™ ; PA/a/2001/010282) LARIMSH Product The objective of the present work is to evaluate the effect of LAR IMS H™ in pacients with R heumatoid Arthtitis and Osteoar- thritis trated with diverse types of drugs within the last 5 years and did not achieve an appropiate response for pain control, joint dis placement dis ability and joints deformed. OBJECTIVES Pain evaluation in patients was carry out using the Huskisson test. Briefly, this test is carry out using an analogous 10 cm. visual scale (horizontal or vertical), with an end labeled with “W ithout P ain” and the oppos ite end labeled with “P ain as high as possible”, has great sensibility and ability to reproduce in the quanti- fication of joint pain magnitude for patients with R heumatoid Arthritis , when the patient is asked to point over the line his pain intensity. This has been proveen in several studies, that is why it is so widely used. (5,6) The clasic scheme for a visual scale of 10 cm. long is shown. Patient self-evaluated pain METHODS Walk disability The walk disability had been evaluated acording to an modified version of the Health Assesment Questionaire – Disability Index (HAQ-DI), in the spanish version of the questionaire (S panish-HAQ- DI). (5) E ach patient receive 1 ml. orally and 2 ml. topi- cal of LAR IMS H during the evaluation time. RESULTS In the Table, the effect of LAR IMS H in P ain and Walk dis ability is analized for chronic arthritis patients with an average age of 67 years and 13 years of desease evolution and including 10 female and one male. In the P ain scale and Walk limitation evaluation a significan decrease of pain of a 62% (8 vs 3, P<0.05, n=11) and a decrease in the Walk limitation from 80% to a 25% is shown. CONCLUSION The lack of success for the conventional medicine and their unwanted side- effects are causes for interrupt and/or irregularities in the medical treatments of the Arthritis . T he s ignificative res ults with LAR IMS H in the treated patients s hows that exists a great posibility for this alternative treatment in these rheumatic diseases, with almost null side effects. Without Pain Pain as high as possible (1) An Overview of Arthritis and R ealted Disorders, C olorado Healthsite,http://www.coloradohealthnet.org/arthritis/arth_over.html (2) What is Arthritis? , Arthritis Web S ite,http://www.arthirtiswebsite.com/heath_library/basics/what_is.html (3) E vans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroideal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: A record linkage case-control study. BMJ 331:22-26, 1995 (4) R odriguez R , Garcí a M, E fecto de fracciones hidrocarbonadas combinadas con metales activos sobre la disminució n del dolor en pacientes con cáncer, XXI Congreso Nacional de Ciencias Fisioló gicas (O-62) Qro. Qro, 14-08-1998 (5) Francisco R amos Niembro, E nfermedades R eumáticas, Criterios y Diagnó sticos, Ed. Mc Graw-Hill Interamericana, 1999, pp. 15- 47 (6) Huskisson EC, Meassurement of pain. Lancet. 1974; ii:1127-1131 (7) Arthritis F oundation, Alternative T herapies , Arthritis F oundation Web S ite, http://www.arthritis .org/alttherapies / (8) Boers M, Tugwell P, Felson DT, et al. World Head Organization an the International League of Association for R heumatology core E ndpoints of s ymptoms modifying antirheumatic drugs in rheumatoid arthritis clinical trains , J ournal of R heumatology, 1994; 21(S uppl. 41): 86-89 (9) Callahan LF, Brooks R H, S ummey JA, et al. Quantitative pain assesment for routine care of rheumatoid arthritis patients, using a pain scalebased on activitiesof daily living and visual analog pain scale. Arthritis R heum. 1987; 30:630-636 (10) Debra F Lappin. Arthritis: What We Know Today. S cientific Workshops, Conferences, and Committees R eports. Friday, May 30, 1997. http://www.niams.nih.gov/ne/reports/sci_wrk/1997/lappin.htm (11) E lliot D R osenstein, Agentes tó picos en el tratamiento de las enfermedades reumáticas. R heumatic Disease Clinics of North America (E dició n españ ola). 1999; 4:913-930 (12) E scalante A, Galarza-Delgado D, Beardmore TD, et al. Cross-cultural adaptation of a brief outcome questionnaire for spanish speaking arthritis patients. Arthritis R heum. 1996; 39: 93-100 (13) What is it? , Arthritis Web S ite, http://www.arthirtis webs ite.com/facts /form/oa.js p REFERENCES T R A D IT IO N A L T R A D IT IO N A L + L A R IM S H L A R IM S H O N L Y B E F O R E L A R IM S H A F T E R L A R IM S H B E F O R E L A R IM S H A F T E R L A R IM S H 1 F 7 3 h o m e - w a s h e r - ir o n e r O A k n e e s fin g e rs h a n d s 2 n a p ro x e n - O ra l : 1 T o p ic a l : 2 8 2 7 0 % 2 0 % 2 F 8 7 h o m e - w a s h e r - ir o n e r O A k n e e s e lb o w s s h o u ld e rs lu m b a r ve rte b ra e 1 5 d ic lo fe n a c o , in d om e ta c in a - O ra l : 1 T o p ic a l : 2 9 4 8 0 % 3 0 % 3 F 5 4 to r tilla m a ke r O A h a n d s s h o u ld e rs 2 d ic lo fe n a c o - O ra l : 1 T o p ic a l : 2 6 2 - - 4 F 5 3 o f f ic e s e c re ta ry R A k n e e s e lb o w s h a n d s 1 5 m e to tr e x a te , c lo ro q u in a , kn e e s u rg e ry - O ra l : 2 T o p ic a l : 2 1 0 5 9 0 % 4 0 % 5 F 6 7 h o m e - w a s h e r - ir o n e r R A h a n d s fin g e rs e lb o w s s h o u ld e rs 2 4 m e tro te x a te , c lo ro q u in a , h a n d s u rg e ry (7 tim e s ) - O ra l : 2 T o p ic a l : 2 1 0 2 9 0 % 2 0 % 6 F 5 2 h o m e - w a s h e r - ir o n e r R A h a n d s k n e e s h ip a n c le s 3 4 d ic lo fe n a c o , in d om e ta c in a , p a ra c e ta m o l, n a p ro x e n o , m e to tr e x a te , c lo ro q u in a , g o ld s a lts m e tic o rte n , p la qu e n il, d ilo te n , la r im s h O ra l : 1 T o p ic a l : 2 7 1 8 0 % 1 0 % 7 M 7 6 w a lk in g s a le s O A k n e e s a n c le s lu m b a r ve rte b ra e 1 5 d ic lo fe n a c o , n a p ro x e n , in d om e ta c in a - O ra l : 1 T o p ic a l : 2 9 4 9 0 % 2 0 % 8 F 7 7 h o m e - w a s h e r - ir o n e r O A h a n d s k n e e s lu m b a r ve rte b ra e 1 7 n a p ro x e n , d ic lo fe n a c o , p a ra c e ta m o l, a s p ir in - O ra l : 1 T o p ic a l : 2 7 2 5 0 % 1 0 % 9 F 6 5 h o m e - w a s h e r - ir o n e r O A k n e e s c e rvic a l d o rs a l lu m b a r ve rte b ra e 5 n a p ro x e n , d ic lo fe n a c o , a s p ir in - O ra l : 1 T o p ic a l : 2 8 4 8 0 % 4 0 % 1 0 F 7 2 h o m e - w a s h e r - ir o n e r O A k n e e s h a n d s 5 n a p ro x e n , d ic lo fe n a c o , a s p ir in - O ra l : 1 T o p ic a l : 2 8 3 8 0 % 3 0 % 1 1 F 6 3 w a s h e r - iron e r - d ry c le a n e r O A k n e e s h a n d s 1 0 d ic lo fe n a c o - O ra l : 1 T o p ic a l : 2 7 3 6 0 % 2 0 % P A IN S C O R E S W A L K D IS A B IL IT Y (% ) T R E A T M E N T S # S E X A G E E M P L O Y M E N T D IA G N O S IS A F F E C T E D J O IN T S E V O L U T IO N O F D IS E A S E (y e a rs )
